Research Article
Upregulated Solute Carrier SLC39A1 Promotes Gastric Cancer Proliferation and Indicates Unfavorable Prognosis
Table 2
Kaplan–Meier overall survival (OS) analyses.
| Characteristic | Case (n = 154) | Median OS (months) | 5-year OS (%) | -value |
| Age | ≤60 yrs | 64 | 27.0 | 33.3 | 0.759 | >60 yrs | 90 | 34.0 | 33.5 |
| Sex | Female | 43 | 33.0 | 42.4 | 0.850 | Male | 111 | 33.0 | 29.7 |
| Localization | Upper 1/3 | 85 | 35.0 | 31.1 | 0.446 | Lower 2/3 | 69 | 27.0 | 34.9 |
| Tumor diameter | ≤5.0 cm | 109 | 55.0 | 43.1 | 0.003 | >5.0 cm | 45 | 19.0 | 22.6 |
| Differentiation | Well/moderate | 56 | 57.0 | 43.6 | 0.114 | Poor | 98 | 32.0 | 28.2 |
| T stage | T1/T2 | 58 | 57.0 | 46.4 | 0.002 | T3/T4 | 96 | 24.0 | 26.1 |
| LN metastasis | Negative | 54 | 60.0 | 47.9 | 0.001 | Positive | 100 | 23.0 | 25.3 |
| SLC39A1 protein level | Low | 77 | 57.0 | 49.0 | 0.001 | High | 77 | 22.0 | 21.2 |
|
|